This information was originally presented at the NCCN 11^th Annual Congress: Hematologic Malignancies™ held in New York, New York.

This information was originally presented at the NCCN 11^th Annual Congress: Hematologic Malignancies™ held in New York, New York.

This information was originally presented at the NCCN 10^th Annual Congress: Hematologic Malignancies™ held in San Francisco, California.

This information was originally presented at the NCCN 10^th Annual Congress: Hematologic Malignancies™ held in San Francisco, California.

This information was originally presented at the NCCN 10^th Annual Congress: Hematologic Malignancies™ held in San Francisco, California.

Treatment of hematologic malignancies is increasingly complex. Issues relating to pathology, transplantation, and various new therapies require oncologists and hematologists to stay abreast of breakthrough advances.

Treatment of hematologic malignancies is increasingly complex. Issues relating to pathology, transplantation, and various new therapies require oncologists and hematologists to stay abreast of breakthrough advances.

Lymphoma is a well-recognized complication in patients infected with HIV. Although its incidence has declined since the advent of antiretroviral therapy, it remains higher than in the general population.

Hematopoietic cell transplantation (HCT) provides a life-prolonging or potentially curative treatment option for patients with hematologic malignancies.